Study for children with certain relapsed leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial looks at treatment for children whose leukemia has come back for the first time. It focuses on a specific type of leukemia and risk level to see whether the approach improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your leukemia is either B-cell or T-cell type
- This is the first time the leukemia has returned
- Your risk level is medium or high
- You do not have mature B-cell leukemia
- You do not have acute mixed-phenotype leukemia
- Your leukemia does not have the BCR/ABL fusion gene
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a standard treatment plan for children who have just been diagnosed with acute lymphoblastic leukemia (ALL). It aims to guide the best initial treatment for certain cell types of ALL and help improve outcomes while avoiding specific higher-risk subtypes.
This trial tests whether adding arsenic trioxide to standard chemotherapy can help children whose medulloblastoma has come back or is hard to treat, especially if the tumor has certain genetic changes. The goal is to see if this combination can shrink tumors or slow their growth.
This study looks at different treatments for children whose leukemia (B-cell acute lymphoblastic leukemia) has returned after initial treatment. It tests new drug combinations and compares them to standard chemotherapy to find the best way to put the cancer back into remission.
This trial tests a treatment plan for children with newly diagnosed acute lymphoblastic leukemia (ALL) that is considered standard-risk. It aims to see if the treatment is effective and safe.
This Phase 2 study tests a combination treatment for children, teens, or young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or did not respond to initial therapy. It may help patients who cannot safely receive certain standard medicines like anthracyclines or who cannot tolerate PEG-asparaginase.
This study looks at genetic (DNA) differences to understand acute lymphoblastic leukemia (ALL) in Indian children and how treatments may fit better. You may be able to join if your child is newly diagnosed, meets the study’s treatment plan rules, and provides consent.
Hear when a new Arsenic Trioxide trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.